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ABSTRACT 
 
Aims: 
We tested the hypothesis that candesartan improves outcomes in heart failure with mid-
range ejection fraction (HFmrEF, EF 40-49%). 
Methods and Results: 
In 7598 patients enrolled in the CHARM Programme (HF across the spectrum of EF), we 
assessed characteristics, outcomes and treatment effect of candesartan according to EF. 
Patients with HFmrEF (n=1322; 17%) were similar to those with HFrEF (n=4323; 57%) with 
respect to some characteristics, and intermediate between HFrEF and HFpEF (n=1953; 26%) with 
respect to others. Over 2.9 years mean follow-up, the incidence rates for the primary outcome of 
cardiovascular death or HF hospitalization were 15.9, 8.5 and 8.9 per 100-patient years in HFrEF, 
HFmrEF and HFpEF. In adjusted analyses, the rates of the primary outcome declined with increasing 
EF up to 50%. 
For treatment effect, the incidence rates for the primary outcome for candesartan vs. 
placebo were in HFrEF: 14.4 vs. 17.5 per 100 patient-years (hazard ratio [95% confidence interval] 
0.82 [0.75-0.91], p<0.001); in HFmrEF: 7.4 vs. 9.7 per 100 patient-years (0.76 [0.61-0.96] p=0.02); 
and in HFpEF: 8.6 vs. 9.1 per 100 patient-years (0.95 [0.79-1.14] p=0.57). For recurrent HF 
hospitalization, the incidence rate ratios were in HFrEF: 0.68 (0.58-0.80), p<0.001; in HFmrEF: 0.48 
(0.33-0.70), p<0.001; and in HFpEF: 0.78 (0.59-1.03), p=0.08. With EF as a continuous spline variable, 
candesartan significantly reduced the primary outcome until EF well over 50% and recurrent HF 
hospitalizations until EF well over 60%. 
Conclusion: 
Candesartan improved outcomes in HFmrEF to a similar degree as in HFrEF. 
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INTRODUCTION 
The 2016 European Society of Cardiology heart failure (HF) guidelines recognized the gap in 
evidence for patients with HF and ejection fraction (EF) in the middle range of 40-49% (HFmrEF) 
between HF with reduced (HFrEF; <40%) and preserved (HFpEF; ≥50%) EF (1, 2). Emerging data from 
registry and cohort settings are inconsistent regarding whether clinical characteristics in HFmrEF 
may be more similar to in HFrEF or HFpEF or intermediate (3-10). Little is known regarding cause-
specific outcomes, which may be especially important for testing existing or developing novel 
interventions for HFmrEF. Finally, although EF in HFmrEF is not normal, there is currently no 
evidence based therapy in this EF category. 
The Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity 
(CHARM) Programme studied patients with symptomatic heart failure across the spectrum of EF and 
represents an opportunity to assess the characteristics, outcomes and efficacy of angiotensin 
receptor blockade across the entire EF spectrum. In CHARM, Increasing EF was associated with 
better outcomes until approximately 45%, without further improvement at higher EFs (11). In 
CHARM-Preserved, which enrolled patients with LVEF >40%, candesartan did not significantly reduce 
cardiovascular death or HF hospitalization (unadjusted hazard ratio 0.89 [95% CI 0.77–1.03], 
p=0.118; covariate adjusted 0.86 [0.74–1.0], p=0.051). However, it was effective in HFrEF, and in 
CHARM-Overall, there was no heterogeneity with respect to EF (p=0.33). The potential benefit 
in the HFmrEF range has not been specifically reported (12).  We used data from the CHARM 
Programme to assess the relationship between EF and patient characteristics and outcomes, and 
tested the hypothesis that candesartan improves outcomes in HFmrEF. 
 
METHODS 
Patients 
The rationale and design (13) and main outcomes (12) of the CHARM Programme have been 
described. Briefly, 7599 patients with symptomatic HF were randomized to candesartan vs. placebo 
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in 3 separate trials, CHARM-Added (EF ≤40% treated with an ACE-inhibitor, n=2548), CHARM-
Alternative (EF ≤40% intolerant to an ACE-inhibitor, n=2028), and CHARM-Preserved (EF >40%, 19% 
treated with an ACE-inhibitor, n=3023). For the present analysis, the 7598 patients with available 
integer digit EF were divided into HFrEF, EF<40%; HFmrEF, EF 40-49%; and HFpEF, EF≥50%. 
The primary outcome was time to cardiovascular (CV) death or first HF hospitalization. 
Additional pre-specified outcomes included times to first HF hospitalization, all-cause 
hospitalization, CV death, and all-cause death, and rate of recurrent heart failure hospitalizations. 
 
Statistical methods 
Baseline characteristics across the 3 EF groups were summarized using means and standard 
deviations or medians (interquartile ranges) for continuous data, or percentages for categorical data, 
respectively. Trend tests were performed across EF groups using linear regression for continuous 
and chi square tests for categorical data. 
The association between EF and outcomes was assessed in the overall population 
(irrespective of treatment assignment) with EF as 3 categories and as a continuous independent 
variable, and outcomes as the dependent variable. For associations between EF and outcomes, 
incidence rates per 100 patient-years were calculated for each outcome in each EF group. The 
associations between EF groups and all time to first outcomes were assessed with univariable and 
multivariable Cox regressions and between EF groups and rates of recurrent HF hospitalizations 
using univariable and multivariable negative binomial regression models which take both time to 
and number of events into account. The multivariable Cox models violated the proportional hazards 
assumption; therefore stratified models using age, treatment assignment and body mass index 
deciles were entered as stratification factors, after which the proportional hazards assumption was 
no longer violated. The adjusted associations between EF as a continuous variable and outcomes 
were plotted using multivariable restricted cubic splines models with 5 knots, using Poisson 
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regression models to estimate incidence rates for time to first event outcomes and using negative 
binomial regression for the recurrent HF hospitalizations outcome. 
The effect of candesartan vs. placebo was assessed in the 3 EF categories and in the overall 
population with EF as a continuous variable. Incidence rate ratios were calculated for candesartan 
vs. placebo for each outcome within each EF group. The interactions between treatment and EF 
category were also examined using Cox models. Within EF categories, the effect of candesartan on 
time to the primary composite outcome was assessed with Kaplan-Meier analysis, for the primary 
and 4 additional time to first event outcomes from the original CHARM Programme with univariable 
Cox regressions, and for the recurrent outcome using univariable negative binomial regression. For 
EF as a continuous variable, the effect of candesartan was modeled using univariable restricted cubic 
splines with 3 knots, using Poisson regression for time to first outcomes and negative binomial 
regressions for the recurrent outcome. 
Patients lost to follow-up (n=10) were censored alive at last follow-up. Statistical analyses 
were performed in Stata v. 14 (College Station, USA). The CHARM Programme was approved by local 
ethics boards. All patients provided written informed consent. 
 
RESULTS 
EF and baseline characteristics 
Of 7599 patients enrolled in CHARM, EF was available in 7598 patients with 4323 (57%) 
patients falling into the HFrEF  range, 1322 patients (17%) falling into the HFmrEF range,  and 1953 
patients (26%) falling into the HFpEF range. HFmrEF resembled HFrEF regarding most characteristics 
including age, systolic blood pressure, percent women, previous myocardial infarction, and atrial 
fibrillation (Table 1). HFmrEF was intermediate between HFrEF and HFpEF with regard to history of 
hypertension, distribution of NYHA class, and body mass index (p for trend over EF categories <0.001 
for all). Some characteristics, such as diabetes mellitus (p for trend =0.71), were similarly prevalent 
in all 3 EF categories. 
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EF and outcomes (irrespective of treatment assignment) 
Table 2 shows event rates and unadjusted and adjusted hazard ratios for time to event 
outcomes and incidence rate ratios for the recurrent outcome for each of the 3 EF groups 
(irrespective of treatment assignment). Over a mean follow-up of 2.9 years overall, there were 15.9, 
8.5, and 8.9 primary events (cardiovascular death or first HF hospitalization) per 100 patient-years in 
HFrEF, HFmrEF, and HFpEF, respectively; and 20.0, 10.8, and 11.1 recurrent HF hospitalizations per 
100 patient-years, respectively. The incidence rates for the first HF hospitalization, CV death and all-
cause death were similar in patients with HFmrEF and those with HFpEF, and considerably lower 
than in those with HFrEF.  The incidence of all-cause hospitalization was somewhat lower in HFmrEF 
than in HFrEF and HFpEF. 
Figure 1 shows adjusted incidence rates for each outcome according to continuous EF. For 
the primary, CV death, and all-cause death outcomes, the risk decreased steeply with increasing EF 
until EF around 50%, and the risk was flat thereafter. For first HF hospitalization, first all-cause 
hospitalization and recurrent HF hospitalization, the risk decreased with increasing EF until EF 
around 40%. The p overall and p for non-linearity for EF and all outcomes were <0.001. 
 
EF and candesartan treatment effect 
Figure 2 shows Kaplan-Meier curves with time to the primary outcome for each of the 3 EF 
groups. Candesartan showed a beneficial effect compared to placebo in HFrEF and HFmrEF but not 
in HFpEF. Table 3 shows event rates and unadjusted hazard ratios and incidence rate ratios for each 
outcome in each EF group according to treatment assignment. In HFrEF and HFmrEF, candesartan 
significantly reduced the primary composite outcome, first HF hospitalization and recurrent HF 
hospitalization. In HFrEF, candesartan also significantly reduced CV death and all-cause death. In 
HFpEF, candesartan did not significantly reduce any outcome, but for recurrent HF hospitalizations, 
the hazard ratio (HR) (95% confidence interval [CI]) was 0.78 (0.59-1.03, p=0.08). There was no 
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significant interaction between EF group and treatment in the association between treatment and 
outcomes, except for the all-cause death outcome.  
Figure 3 shows unadjusted treatment effects for each outcome according to continuous EF. 
The hazard ratios and upper 95% CIs were always below 1.0, indicating benefit with candesartan, up 
to and beyond EF~50% for the primary composite and first HF hospitalization outcomes, and up to 
EF~60% for the recurrent HF hospitalizations outcome. Candesartan reduced each of CV death, all-
cause death and all-cause hospitalization only at the lower end of the EF spectrum. 
 
DISCUSSION 
In this large and long-term clinical trial programme of patients with heart failure including 
ejection fractions across the entire spectrum, we found that 1) HFmrEF resembled HFrEF with 
respect to many baseline characteristics, including age, gender and history of myocardial infarction; 
2) that HFmrEF resembled HFpEF with respect to lower risk of HF and CV events; and 3) that 
candesartan reduced the composite of CV death and HF hospitalization, as well as first and recurrent 
HF hospitalizations, in HFrEF and HFmrEF but not in HFpEF, although there was no statistical 
interaction between EF category and candesartan treatment effect. 
We recognize, along with others, that EF is not an optimal classifier in HF (1, 14), that cut-
offs are arbitrary, and that other tools to identify disease specific phenotypes may emerge 
as more important than EF. But EF remains the most commonly used classifier. Clinical trials, drug 
labels, treatment guidelines, and reimbursement schemes are based on EF cut-offs (15). EF may 
change with treatment and over time, but this appears highly variable depending on setting and 
baseline treatment (3, 10, 16). HFmrEF constitutes up to 20% of the HF population (4, 17). Thus, 
whether a separate phenotype or part of a continuum, HFmrEF is common, and data regarding 
patient characteristics and outcomes and response to therapy are clinically relevant and relevant for 
trial design. 
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The boundary for “normal EF” remains controversial but the EchoNoRMAL study suggested a 
lower limit of 49-57%, depending on age, sex and ethnicity(18).  According to the American Society 
of Echocardiography and European Association of Cardiovascular Imaging, the normal EF and normal 
range (±2 standard deviations) is 62% (52-72%) in men and 64% (54-74%) in women(19). In HF, the 
EF distribution was bimodal in the OPTIMIZE-HF Registry (20) and in Olmsted County (21) but 
unimodal and normally distributed in CHARM (11). Regardless of distribution, most studies have 
consistently shown that patients with EF in the 40-50% range constitute up to 20% of the HF 
population(4, 11, 17, 20, 21). Thus HFmrEF is not infrequently encountered in clinical settings. 
 
EF and baseline characteristics 
HFmrEF is often termed “intermediate” but our findings challenge this. Some baseline 
characteristics in HFmrEF were intermediate between HFrEF and HFpEF. However, HFmrEF distinctly 
resembled HFrEF in several important aspects, including age, sex and ischæmic heart disease and 
history of myocardial infarction, consistent with other emerging analyses (8). With improved and 
earlier treatment for myocardial infarction, the importance of the HFmrEF category may also be 
increasing over time. While diabetes was equally common in all EF categories it may contribute 
differently to HF, by contributing to ischemic heart disease and myocardial infarction in lower EF and 
together with obesity and other comorbidities potentially to microvascular inflammation, fibrosis 
and diastolic dysfunction in higher EF (22, 23). 
 
EF and outcomes 
Prior studies have described the association of EF with outcomes in HF: the risk for 
cardiovascular outcomes declined as EF increased up to 45% in the Meta-analysis Global Group in 
Chronic Heart Failure (MAGGIC)(24) and up to 40% in a previous analysis from CHARM(11). In the 
present analysis, crude CV event rates were similar in HFmrEF and HFpEF and much lower than in 
HFrEF; and analogously, the adjusted hazard ratios demonstrated lower risk in HFmrEF and HFpEF 
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compared to HFrEF. However, regarding the importance of incremental increases in EF, the HFmrEF 
group was similar to HFrEF in that an increasing EF was associated with improving prognosis (up-
sloping curves in spline analyses in Figure 1 up to EF ~50%), whereas within the HFpEF group, 
changes in EF were not related to prognosis (flat curves). This is also consistent with the risk of non-
CV events, particularly all-cause hospitalization, increasing with the highest EF, where comorbidity 
and frailty may be drivers of both deconditioning and HF symptoms (which may be difficult to 
interpret and in trials may have led to inclusion of patients without HF), as well as non-CV outcomes. 
 
EF and candesartan treatment effect 
Across the entire EF spectrum and for all outcomes, there was no significant interaction 
between EF and treatment effect. Nevertheless, given the different effect in the separate HFrEF and 
HFpEF trials in CHARM, extensive trial data that have been positive in HFrEF and neutral in HFpEF, 
and new designation of HFmrEF, this post-hoc analysis of pre-specified EF strata was considered 
justified, novel, and important. 
We found that in HFrEF and HFmrEF candesartan appeared to significantly reduce the 
primary composite of time to CV death or HF hospitalization and time to HF hospitalization, as well 
as the novel outcome recurrent HF hospitalization, with hazard ratios and incidence rate ratios 
similar in HFrEF and HFmrEF and clinically meaningful approximately 20% reductions in time to first 
CV events and more than 30% reductions in recurrent HF hospitalization. However, since event 
rates were lower in HFmrEF than in HFrEF, the absolute risk reductions will also be lower in 
HFmrEF than in HFrEF. Spline analyses with EF as a continuous variable confirmed these findings, 
with candesartan efficacy constant at lower EFs and generally beginning to decline as EF moved 
above 50%. In PARADIGM-HF (HFrEF defined as EF ≤40%), the beneficial effect of sacubitril/valsartan 
was similar regardless of EF (25). This is consistent with our observations of a similar treatment 
effect of candesartan regardless of EF up to ~50% (flat sections of curves in Figure 3). In TOPCAT, 
spironolactone was not effective in HFpEF defined as EF ≥45%, but there was a suggestion of 
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potential efficacy with lower EF and declining efficacy with increasing EF(26); this is consistent with 
our observations of declining effect of candesartan with increasing EF in and above the HFmrEF 
range (upsloping sections of curves in Figure 3). The present findings now demonstrate HF treatment 
efficacy in the HFmrEF range. These findings raise the possibility that the arbitrary EF 35% or 40% 
cut-offs used in many previous and trials may have excluded patients who would potentially have 
derived benefit from the many interventions proven to be effective in HFrEF. 
 
Limitations 
The sample size of 7958 provided convincing efficacy results for the lower EF spectrum and 
narrow confidence intervals throughout a broad EF spectrum. However, at the extremes of EF 
statistical power was limited. Multiple outcomes and testing as well as the post-hoc nature of this 
analysis increase the risk that some of the findings may have occurred by chance. EF may change 
over time and there is inherent variability in EF measurements but this is likely in both directions 
without systematic bias, and with this large sample size, the consequences of measurement error 
are reduced. There is an even-digit bias in assigning EF and unconventional, uneven, EF categories, 
may reduce the risk of systematic miss-classification (28). However, with existing trial cut-off and our 
focus specifically on the newly designated HFmrEF category, we conducted our analyses using even 
digit cut-offs. 
 
Conclusion 
HFmrEF resembled HFrEF with regard to some characteristics and was intermediate with regard to 
others. HFmrEF resembled HFpEF with regard to risk of CV and HF outcomes, which was lower than 
in HFrEF. Importantly, candesartan improved outcomes in the HFmrEF range. This finding should 
be interpreted with caution because this was a post-hoc analysis and there was no statistical 
interaction between EF category and candesartan treatment. Thus whether patients in the 
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HFmrEF range might benefit from therapies shown to be effective in HFrEF must be 
considered a hypothesis only. 
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FIGURE LEGENDS 
 
Figure 1. Association between EF as a continuous variable and outcomes (regardless of treatment 
assignment). Adjusted Incidence rates (per 100 patient-years) and 95% confidence intervals for the 6 
outcomes according to EF as a continuous variable. Adjusted for the same variables as in Table 2. 
The range shaded blue is the HFmrEF range. 
 
Figure 2. Effect of candesartan on the primary outcome by EF category. Kaplan-Meier time-to-
event curves for candesartan (red) vs. placebo (blue) for the primary composite outcome: time to 
cardiovascular death or first heart failure hospitalization, for the 3 EF categories. Large graphs show 
y-axis up to 1.0; inserted graphs show y-axis up to 0.4. 
 
Figure 3. Effect of candesartan on all outcomes by EF as a continuous variable. Unadjusted 
incidence rate ratios and 95% confidence intervals for the candesartan treatment effect for the 6 
outcomes according to EF as a continuous variable. The range shaded blue is the HFmrEF range. The 
red arrow indicates the EF at which the 95% confidence interval for the hazard ratio for candesartan 
vs. placebo was no longer < 1.0. 
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TABLES 
Table 1. Baseline characteristics according to EF category 
Variable name 
EF <40%, HFrEF 
n=4323 (57%) 
HFmrEF, EF 40-49% 
n=1322 (17%) 
EF ≥50%, HFpEF 
n=1953 (26%) 
 p for 
trend* 
Candesartan 2155 (49.8%) 667 (50.5%) 980 (50.2%) 0.77 
Clinical     
Age (years) 65 ± 11 65 ± 11 67 ± 11 0.001 
Female 1116 (25.8%) 395 (29.9%) 888 (45.5%) <0.001 
Race 
   
0.035 
    European 3865 (89.4%) 1237 (93.6%) 1767 (90.5%) 
     Black 194 (4.5%) 43 (3.3%) 89 (4.6%) 
     Other 264 (6.1%) 42 (3.2%) 97 (5.0%) 
 NYHA 
   
<0.001 
    II 1460 (33.8%) 763 (57.7%) 1193 (61.1%) 
     III 2713 (62.8%) 550 (41.6%) 721 (36.9%) 
     IV 150 (3.5%) 9 (0.7%) 39 (2.0%) 
 EF 30 (23, 35) 44 (41, 46) 58 (53, 63) <0.001 
BMI 27.1 (24.1, 30.3) 27.8 (25.0, 31.2) 28.6 (25.4, 32.6) <0.001 
SBP, mm Hg 126 (112, 140) 130 (120, 145) 140 (124, 150) <0.001 
DBP, mm Hg 76 (70, 80) 80 (70, 85) 80 (70, 85) <0.001 
Physical exam edema 968    (22.4%) 306    (23.2%) 579    (29.6%) <0.001 
Creatinine, mg/dl 1.21 ± 0.85 1.16 ± 0.43 1.11 ± 0.41 0.001 
HF cause 
        Ischemic 2810    (65.0%) 885    (66.9%) 985    (50.4%) <0.001 
    Idiopathic 1017    (23.5%) 173    (13.1%) 137    (7.0%) <0.001 
    Hypertensive 275    (6.4%) 168    (12.7%) 538    (27.5%) <0.001 
Medical History 
    Previous HF  3189    (73.8%) 926    (70.0%) 1310    (67.1%) <0.001 
MI 2520    (58.3%) 761    (57.6%) 722    (37.0%) <0.001 
Angina pectoris 2388    (55.2%) 813    (61.5%) 1150    (58.9%) 0.001 
CABG 1075    (24.9%) 336    (25.4%) 380    (19.5%) <0.001 
PCI 659    (15.2%) 241    (18.2%) 328    (16.8%) 0.06 
Stroke 376    (8.7%) 123    (9.3%) 164    (8.4%) 0.8 
DM 1236    (28.6%) 378    (28.6%) 549    (28.1%) 0.71 
Hypertension 2100    (48.6%) 743    (56.2%) 1342    (68.7%) <0.001 
AF 1132    (26.2%) 339    (25.6%) 612    (31.3%) <0.001 
Pacemaker 393    (9.1%) 100    (7.6%) 144    (7.4%) 0.015 
Current Smoker 668    (15.5%) 210    (15.9%) 236    (12.1%) <0.001 
ICD 160    (3.7%) 21     (1.6%) 10     (0.5%) <0.001 
Cancer 273    (6.3%) 90     (6.8%) 150    (7.7%) 0.047 
Medical treatment 
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ACE-inhibitor 2446    (56.6%) 359    (27.2%) 320    (16.4%) <0.001 
ß-blocker 2385    (55.2%) 763    (57.7%) 1055    (54.0%) 0.61 
Diuretic 3831    (88.6%) 984    (74.4%) 1470    (75.3%) <0.001 
Spironolactone 889    (20.6%) 151    (11.4%) 232    (11.9%) <0.001 
Digitalis 2296    (53.1%) 465    (35.2%) 492    (25.2%) <0.001 
Calcium antagonist 544    (12.6%) 319    (24.1%) 678    (34.7%) <0.001 
Other vasodilator 1713    (39.6%) 524    (39.6%) 726    (37.2%) 0.080 
Oral anticoagulant 1525    (35.3%) 327    (24.7%) 485    (24.8%) <0.001 
Antiarrhythmic 552    (12.8%) 150    (11.3%) 191    (9.8%) <0.001 
Aspirin 2335    (54.0%) 816    (61.7%) 1095    (56.1%) 0.022 
Other antiplatelet 181    (4.2%) 61     (4.6%) 113    (5.8%) 0.006 
Lipid-lowering 1782    (41.2%) 591    (44.7%) 779    (39.9%) 0.59 
Numbers are n (%), mean ± standard deviation, and median (interquartile range) 
*p for trend over EF categories 
 
NYHA, New York Heart Association 
EF, ejection fraction 
SD, standard deviation 
BMI, body mass index 
HF, heart failure 
MI, myocardial infarction 
CABG, coronary artery bypass graft 
PCI, percutaneous coronary intervention 
ICD, implantable cardioverter-defibrillator 
ACE, angiotensin converting enzyme 
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Table 2. Outcomes according to EF category (irrespective of treatment assignment) 
 
EF <40% 
n=4323 
EF 40-49% 
n=1322 
EF >=50% 
n=1953 
Follow-up (years, mean ± SD) 2.79 ± 1.02 2.93 ± 0.76 2.91 ± 0.70 
CV Death + HF Hospitalization 
1692 (39.2%) 
15.9 (15.2-16.7) 
 per 100pyr 
305 (23.1%) 
8.5 (7.6-9.5) 
per 100pyr 
462 (23.7%) 
8.9 (8.1-9.7) 
per 100pyr 
Unadjusted HR 
1.79 (1.61-1.98) 
< 0.001 
0.96 (0.83-1.11) 
0.61 
Reference 
Adjusted HR*  
1.58 (1.40-1.79) 
< 0.001 
1.00 (0.85-1.17) 
0.98 
Reference 
HF Hospitalization 
1115 (25.8%) 
10.5 (9.9-11.1) 
per 100pyr 
216 (16.3%) 
6.0 (5.3-6.9) 
per 100pyr 
343 (17.6%) 
6.6 (5.9-7.3) 
per 100pyr 
Unadjusted HR 
1.58 (1.40-1.79) 
< 0.001 
0.92 (0.78-1.09) 
0.34 
Reference 
Adjusted HR* 
1.42 (1.23-1.64) 
< 0.001 
0.94 (0.78-1.13) 
0.55 
Reference 
Recurrent HF Hospitalization, 
Incidence rate# 
20.0 (19.2-20.8) 
per 100pyr 
10.8 (9.8-11.9) 
 per 100pyr 
11.1 (10.2-12.0) 
per 100pyr 
Unadjusted incidence rate ratio 
2.14 (1.83-2.50) 
< 0.001 
1.04 (0.84-1.28) 
0.71 
Reference 
Adjusted IRR* 
1.96 (1.65-2.23) 
< 0.001 
1.21 (0.98-1.49) 
0.07 
Reference 
CV Death 
1079 (25.0%) 
8.9 (8.4-9.5) 
per 100pyr 
167 (12.6%) 
4.3 (3.7-5.0) 
per 100pyr 
214 (11.0%) 
3.8 (3.3-4.3) 
per 100pyr 
Unadjusted HR 
2.37 (2.05-2.75) 
< 0.001 
1.15 (0.94-1.40) 
0.19 
Reference 
Adjusted HR* 
2.20 (1.85-2.61) 
< 0.001 
1.21 (0.98-1.51) 
0.08 
Reference 
All-Cause Hospitalization 
2802 (64.9%) 
38.3 (37.0-39.8) 
 per 100pyr 
767 (58.1%) 
31.0 (28.9-33.3) 
 per 100pyr 
1220 (62.5%) 
35.4 (33.5-37.5) 
per 100pyr 
Unadjusted HR 
1.08 (1.01-1.15) 
0.03 
0.89 (0.81-0.97) 
0.01 
Reference 
Adjusted HR* 
0.99 (0.91-1.08) 
0.85 
0.89 (0.81-0.98) 
0.02 
Reference 
All-Cause Death 
1296 (30.0%) 
10.7 (10.2-11.3) 
 per 100pyr 
209 (15.8%) 
5.4 (4.7-6.2) 
 per 100pyr 
325 (16.6%) 
5.7 (5.1-6.4)  
per 100pyr 
Unadjusted HR 
1.88 (1.66-2.12) 
< 0.001 
0.94 (0.79-1.12) 
0.51 
Reference 
Adjusted HR* 
1.73 (1.49-2.00) 
< 0.001 
0.98 (0.82-1.19) 
0.88 
Reference 
Numbers are event rates (95% CI) per 100 patient-years or hazard ratios (95% CI) 
*Adjusted for sex, ethnicity, New York Heart Association class, systolic blood pressure, heart failure 
cause (ischemic, idiopathic, hypertension), previous heart failure admission, atrial fibrillation, stroke, 
diabetes mellitus, smoking, and cancer, and stratified by Candesartan, age (years) and body mass 
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index (deciles). For recurrent HF model, candesartan, age, and BMI deciles were included as 
covariates. 
#The recurrent event is based on number HF hospitalization episodes and not number of patients 
 
SD, standard deviation 
EF, ejection fraction 
HR, hazard ratio 
IRR, incidence rate ratio 
CV, cardiovascular 
HF, heart failure 
pyr, patient-year 
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Table 3. Treatment effect for 6 outcomes according to 3 EF categories 
 Number and % of Participants with Events, and Incidence Rate per-100 person-year, HR (95%CI), p-values 
 EF ≤ 40 EF 40-49 EF >=50 
CV Death + HF Hosp Placebo Candesartan Placebo Candesartan Placebo Candesartan 
Incidence Rate 906 (41.8%) 
17.5 per 100pyr 
786 (36.5%) 
14.4 per 100pyr 
168 (26.7%) 
9.7 per 100pyr 
137 (20.5%) 
7.4 per 100pyr 
235 (24.2%) 
9.1 per 100pyr 
227 (23.2%) 
8.6 per 100pyr 
Unadjusted HR, p 0.82 (0.75-0.91) p<0.001  0.76 (0.61-0.96) p=0.02  0.95 (0.79-1.14) p=0.57  
 p for interaction (EF group * treatment) = 0.27 
HF Hospitalization Placebo Candesartan Placebo Candesartan Placebo Candesartan 
Incidence Rate 617 (28.5%) 
11.9 per 100pyr 
498 (23.1%) 
9.1 per 100pyr 
122 (18.6%) 
7.1 per 100pyr 
94 (14.1%) 
5.1 per 100pyr 
178 (18.3%) 
6.9 per 100pyr 
165 (16.8%) 
6.3 per 100pyr 
Unadjusted HR, p 0.77 (0.68-0.86) p<0.001  0.72 (0.55-0.95) p=0.02  0.91 (0.74-1.13) p=0.39  
 p for interaction (EF group * treatment) = 0.23 
Recurrent HF Hosp Placebo Candesartan Placebo Candesartan Placebo Candesartan 
Incidence Rate 23.0 per 100yrs 16.8 per 100yrs 14.1 per 100yrs 7.7 per 100yrs 12.5 per 100yrs 9.6 per 100yrs 
Unadjusted IRR, p 0.68 (0.58-0.80) p<0.001  0.48 (0.33-0.70) p<0.001 0.78 (0.59-1.03) p=0.08 
 p for interaction (EF group * treatment) = 0.60 
CV Death Placebo Candesartan Placebo Candesartan Placebo Candesartan 
Incidence Rate 578 (26.7%) 
9.7 per 100pyr 
501 (23.5%) 
8.2 per 100pyr 
90 (13.7%) 
4.8 per 100pyr 
77 (11.5%) 
3.9 per 100pyr 
101 (10.4%) 
3.6 per 100pyr 
113 (11.5%) 
4.0 per 100pyr 
Unadjusted HR, p 0.85 (0.75-0.96) p=0.007  0.81 (0.60-1.11) p=0.19  1.12 (0.85-1.46) p=0.42  
 p for interaction (EF group * treatment) = 0.10 
All-Cause Hospitalization Placebo Candesartan Placebo Candesartan Placebo Candesartan 
Incidence Rate 1417 (65.5%) 
39.5 per 100pyr 
1385 (64.3%) 
37.3 per 100pyr 
393 (60.0%) 
33.1 per 100pyr 
374 (56.2%) 
29.1 per 100pyr 
609 (62.7%) 
35.8 per 100pyr 
611 (62.4%) 
35.1 per 100pyr 
Unadjusted HR, p 0.95 (0.88-1.02) p=0.18  0.89 (0.78-1.03) p=0.12  0.98 (0.88-1.10) p=0.78  
 p for interaction (EF group * treatment) = 0.75 
All-Cause Death Placebo Candesartan Placebo Candesartan Placebo Candesartan 
Incidence Rate 682 (31.5%) 
11.4 per 100pyr 
614 (28.5%) 
10.0 per 100pyr 
114 (17.4%) 
6.0 per 100pyr 
90 (14.2%) 
4.8 per 100pyr 
149 (15.3%) 
5.3 per 100pyr 
176 (18.0%) 
6.2 per 100pyr 
Unadjusted HR, p 0.88 (0.79-0.98) p=0.02  0.79 (0.60-1.04) p=0.10  1.18 (0.95-1.47) p=0.14  
 p for interaction (EF group * treatment) = 0.04 
 
Hosp, hospitalization 
EF, ejection fraction 
HR, hazard ratio 
IRR, incidence rate ratio 
CV, cardiovascular 
HF, heart failure 
pyr, patient-years 
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FIGURES 
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